Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PRGO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Existential event
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Impairment Charges (new) — Q1 2026 results included impairment charges as a non-GAAP adjustment item.
- Debt Default (new) — Company recorded a loss on debt extinguishment during Q1 2026.
Perrigo reports Q1 2026 earnings with impairment charges, debt loss, and infant formula under review
Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read
Key Changes
-
high
Q1 2026 results included impairment charges and a loss on debt extinguishment, signaling potential asset write-downs and financing challenges during the quarter.
Item 2.02 verify on EDGAR → -
high
Infant formula business is under strategic review and excluded from 'Core' metrics; company recorded remediation costs in Q1 with unpredictable future charges expected.
8-K: Non-GAAP adjustments verify on EDGAR → -
high
Multiple non-GAAP adjustments in Q1 including restructuring charges, unusual litigation expenses, and losses on divestitures suggest ongoing operational restructuring.
8-K: Non-GAAP items view on EDGAR → -
medium
Company cannot provide GAAP reconciliation for fiscal 2026 guidance due to unpredictable infant formula charges and restructuring costs, indicating significant forecast uncertainty.
8-K: FY2026 Outlook view on EDGAR →
Summary
Perrigo reported first quarter 2026 earnings that revealed multiple financial challenges. The company recorded impairment charges and a loss on debt extinguishment during the quarter, alongside restructuring costs, unusual litigation expenses, and losses on divestitures.
Most notably, Perrigo's infant formula business is now under strategic review and being excluded from management's 'Core' business metrics, with remediation costs hitting Q1 results. Retail investors should pay attention to the uncertainty surrounding these issues.
Management explicitly stated they cannot reconcile their fiscal 2026 guidance to GAAP metrics because they cannot predict the timing or magnitude of ongoing infant formula charges and restructuring costs. This lack of visibility suggests the company is still working through significant operational and financial challenges. Watch for updates on the infant formula strategic review outcome and whether restructuring charges continue in coming quarters. The combination of asset impairments, debt losses, and business unit reviews typically signals a company in transition, and clarity on the path forward will be critical for assessing investment risk.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Perrigo released Q1 2026 earnings ended March 28, 2026, with non-GAAP adjustments for restructuring, impairments, debt loss, and infant formula costs.
Added in current filing · verify on EDGAR →
On May 6, 2026, Perrigo Company plc (the “Company”) released earnings for the first quarter ended March 28, 2026.
Perrigo disclosed first quarter 2026 financial results for the period ending March 28, 2026. The earnings release is attached as an exhibit to this 8-K filing.
Added in current filing · verify on EDGAR →
•Amortization expense related primarily to acquired intangible assets •Unusual litigation •Restructuring charges and other termination benefits •Impairment charges | •Loss on debt extinguishment | •Infant formula remediation •Loss on divestitures and investment securities •Other non-GAAP adjustments | •Non-GAAP tax adjustments | •Divestitures | •Infant Formula | •Foreign currency translation movement
Q1 2026 results included multiple non-GAAP adjustments: restructuring charges, impairment charges, loss on debt extinguishment, infant formula remediation costs, unusual litigation expenses, and losses on divestitures and investment securities. These items are excluded from management's view of core operating performance.
Added in current filing · verify on EDGAR →
The Company cannot reconcile its ‘All In’ or ‘Core’ expected organic net sales growth, adjusted gross margin, adjusted operating margin, adjusted earnings per share, adjusted diluted earnings per share, or adjusted effective tax rate to the most directly comparable GAAP measures under "Fiscal Year 2026 Outlook from Continuing Operations" without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time. These items include, but are not limited to, uncertainty of non-recurring infant formula related charges and timing and amount of restructuring charges and the income tax effects of these items or other income tax-related events.
Perrigo cannot provide GAAP reconciliations for its fiscal 2026 guidance due to unpredictable items including infant formula charges, restructuring costs, and related tax effects. This indicates ongoing uncertainty around the magnitude and timing of these costs.
Event · Item 9.01 — Financial Statements and Exhibits
Perrigo filed an 8-K to furnish a press release under Item 2.02, typically indicating a financial results or earnings announcement.
Added in current filing · verify on EDGAR →
Press Release issued by Perrigo Company plc on May 6, 2026 furnished solely pursuant to Item 2.02 of Form 8-K.
Perrigo furnished a press release dated May 6, 2026 under Item 2.02, which typically relates to results of operations and financial condition disclosures such as earnings announcements. The actual content of the press release is not included in this 8-K body, only referenced as Exhibit 99.1.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify